
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Generics· June 25, 2026 · 19 min read
By Ran Chen#Generics#Orange Book#FDA Approval

Pricing & Access· June 24, 2026 · 26 min read
Pfizer Portfolio Dossier: Patent Cliffs, Shortages, and Recalls
By Ran Chen#Orange Book#Purple Book#FDA Approval

Generics· June 24, 2026 · 18 min read
When is Generic Imbruvica Available? The 522-Patent Wall and Litigation Settlement Reality
By Ran Chen#Orange Book#Generics#Generic Entry

Generics· June 23, 2026 · 17 min read
Eliquis Generic: Why US Entry is Delayed to April 2028 Despite IRA Cuts
By Ran Chen#Generic Entry#FDA Approval#Orange Book
Biosimilars· June 23, 2026 · 18 min read
Keytruda Biosimilar Tracker: The 7-Developer Race to the 2028 Cliff
By Ran Chen#Biosimilars#Oncology#FDA Approval

Generics· June 23, 2026 · 17 min read
When is Generic Ozempic Available? The US Semaglutide Patent-Cliff Reality
By Ran Chen#Generic Entry#FDA Approval#Orange Book

Generics· June 22, 2026 · 19 min read
Generic Lanreotide Acetate: 505(b)(2) Approvals and Medical-Benefit Coding
By Ran Chen#Generics#FDA Approval#Orange Book

Generics· June 22, 2026 · 19 min read
Generic Vyvanse (Lisdexamfetamine): Shortage Status, API Quotas, and NADAC Price Erosion
By Ran Chen#Generics#Drug Pricing#Supply Chain

Biosimilars· June 22, 2026 · 20 min read
Poherdy (Pertuzumab-dpzb): FDA Approval and Payer Dynamics
By Ran Chen#Biosimilars#FDA Approval#Oncology

Biosimilars· June 21, 2026 · 6 min read
Enbrel biosimilars compared: FDA approvals, patent litigation, and the 2029 market entry
By Ran Chen#Biosimilars#FDA Approval#TNF Inhibitor